

Technology Advisory Committee B Interests Register

Topic: Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

Publication Date: 7th August 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky is pursuing some unrelated consultancy work with Eli Lilly in Alzheimer's.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Eugene McCloskey	Clinical Expert	Direct - Financial	Amgen: Advisory Board and/or Honoraria and/or Research Funding; 2005-Ongoing Consilient Healthcare: Advisory Board and/or Honoraria and/or Research Funding; 2012-2018 Eli Lilly: Advisory Board and/or Honoraria ;2005-2020 Fresenius Kabi: Advisory Board; 2018-2018 Internis; Advisory Board and/or Honoraria and/or Research Funding ;2012-2019 ObsEva: Advisory Board and Research Funding ; 2019-2022		It was agreed that Mr McCloskey's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Radius Inc: Advisory Board and/or Honoraria and/or Research Funding; 2014-2021 UCB: Advisory Board and/or Honoraria and/or Research Funding; 2010-Ongoing		
Eugene McCloskey	Clinical Expert	Direct – non-financial	Director, Osteoporosis Research Limited; 2021-ongoing Member of IOF Board; 2010-ongoing Member of ESCEO Board; 2010-ongoing Chair of Osteoporosis 2000; 2005-ongoing Past Member of ROS Bone Research Academy (Lead of Effectiveness Working Group); 2018-2022		It was agreed that Mr McCloskey's declaration would not prevent him from providing expert advice to the committee.
Stephen Tuck	Clinical Expert	Indirect - Financial	2022 1.6% of total income was from pharmaceutical companies [Amgen donated £10k to support policy and public affairs work to		It was agreed that Mr Tuck's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			promote fracture liaison services from Jan-Dec 2022 UCB donated £10,675 in 2022 for similar work.] 2023 UCB donated £49,395 to support as above. In addition, the following are for Stands at a coming Conference for healthcare professionals: UCB £25k Amgen £25k Thornton & Ross £18.5k Flynn Pharma £6k Stirling Anglian Pharma £2k Theramex did not support us in the last 12 months.		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.		
Philippa Russell	Patient Expert	Indirect - Financial	2022 1.6% of total income was from pharmaceutical companies [Amgen donated £10k to support policy and public affairs work to promote fracture liaison services from Jan-Dec 2022 UCB donated £10,675 in 2022 for similar work.] 2023 UCB donated £49,395 to support as above. In addition, the following are for Stands at a coming Conference for healthcare professionals: UCB £25k		It was agreed that Ms Russell's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Amgen £25k Thornton & Ross £18.5k Flynn Pharma £6k Stirling Anglian Pharma £2k Theramex did not support us in the last 12 months. Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.		
Alison Smith	Patient Expert	Indirect - Financial	2022 1.6% of total income was from pharmaceutical companies [Amgen donated £10k to support policy and public affairs work to promote fracture liaison services from Jan-Dec 2022 UCB donated £10,675 in 2022 for similar work.]		It was agreed that Ms Smith's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			2023 UCB donated £49,395 to support as above. In addition, the following are for Stands at a coming Conference for healthcare professionals: UCB £25k Amgen £25k Thornton & Ross £18.5k Flynn Pharma £6k Stirling Anglian Pharma £2k Theramex did not support us in the last 12 months. Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.		